- Thermo Fisher Scientific. Waltham, Massachusetts, United States; Overview. Download the application note to learn how EVOS Imaging system can enhance cell culture quality control during T-cell.
- Falcon 4 camera: A more sensitive direct electron detector, the Falcon 4 captures images up to 10 times faster than the previous model. Installable on new or existing 300kV and 200kV Thermo Scientific cryo-TEMs, the camera boosts productivity while improving image quality, making it the ideal detector for small proteins.
WALTHAM, Mass., Feb. 3, 2021 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, has signed an agreement with JW Therapeutics, a leading cell therapy company, to ensure non-exclusive commercial access to Thermo Fisher's Gibco CTS Dynabeads CD3/CD28.
About Thermo Fisher Scientific Thermo Fisher Scientific Inc. Is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer.
The agreement will support the clinical development and commercial manufacturing of leading CAR-T (Chimeric Antigen Receptor T-Cells) therapies in China, including JW Therapeutics' lead product relmacabtagene autoleucel ('relma-cel'). Relma-cel is an anti-CD19 CAR-T therapy for third-line treatment for relapsed or refractory ('r/r') B-cell lymphoma. The therapy's new drug application (NDA) has been accepted by China's National Medical Products Administration (NMPA). Relma-cel is expected to be the first CAR-T therapy to be approved as a Category 1 biologics product in China.
The CTS Dynabeads platform is part of Thermo Fisher's proven Cell Therapy Systems (CTS) product portfolio designed to ease the transition from clinical development to commercial manufacturing of T-cell therapies. The CTS product line is a comprehensive portfolio of products designed to work together, from cell isolation/activation and gene transfer to cell expansion, to address cell therapy developers' manufacturing workflow challenges. Thermo Fisher's Gibco CTS Dynabeads provide a scalable platform to streamline therapy development and production while ensuring highly reproducible results.
'As JW Therapeutics progresses through the formal acceptance of a New Drug Application (NDA) for relma-cel, and its commercial plans accelerate, we'll be alongside them ready to rapidly scale,' said Mark Stevenson, executive vice president and chief operating officer, Thermo Fisher Scientific. 'Our strategy to support partners 'in China for China' ensures that we can provide reliable supply and technical expertise as they scale precision medicines.'
'This partnership is a natural extension of an already strong collaboration,' mentioned Dr. Harry Lam, executive vice president and chief technology officer, JW Therapeutics. 'As we approach critical milestones in our commercialization strategy, this partnership will ensure we have the supply to scale up and meet the unmet medical needs of Chinese patients.'
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.
About JW Therapeutics
Co-founded by Juno Therapeutics and Wuxi AppTec, JW Therapeutics is a leading clinical and pre-clinical stage cell therapy company in China with an integrated platform focusing on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors.
JW Therapeutics' vision is to develop innovative cell therapies for the China market to transform the treatment of cancer for Chinese patients. The company has built a comprehensive and differentiated cell therapy pipeline covering both hematological cancers and solid tumors. Its lead product, Relmacabtagene autoleucel ('relma-cel'), an anti-CD19 CAR-T therapy for relapsed or refractory ('r/r') B-cell lymphoma, is expected to be the first CAR-T therapy to be approved as a Category 1 biologics product in China.
For more information, please visit www.jwtherapeutics.com.
Media Contact
Thermo Fisher:
Charlotte McCormack
Phone: 781-622-1202
E-mail: charlotte.mccormack@thermofisher.com
JW Therapeutics:
Brunswick Group
JWTherapeutics@brunswickgroup.com
Zhou Yi
+852 9783 6894
Download Thermo Fisher Scientific Cameras Instructions
Xiaozhu Xiao
+86 13817398201
View original content to download multimedia:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-and-jw-therapeutics-announce-car-t-partnership-in-china-301221244.html
SOURCE Thermo Fisher Scientific
View Comments and Join the Discussion!Thermo Fisher Scientific Locations
WALTHAM, Mass., Jan. 19, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has entered into a definitive agreement to acquire Mesa Biotech, Inc., a privately held molecular diagnostic company, for approximately $450 million in cash. Under the terms of the agreement, Thermo Fisher will pay up to an additional $100 million in cash upon the completion of certain milestones following the close of the transaction. Mesa Biotech has developed and commercialized a PCR-based rapid point-of-care testing platform available for detecting infectious diseases including SARS-CoV-2, Influenza A and B, respiratory syncytial virus (RSV) and Strep A. Mesa Biotech's patented technology expands the availability of gold standard nucleic acid PCR amplification to point-of-care diagnostics. The company is based in San Diego, California and has approximately 500 employees and revenues in 2020 of approximately $45 million. Mesa Biotech's Accula™ Flu A/Flu B, RSV and Strep A tests have obtained 510(k) clearance and Clinical Laboratory Improvements Amendments (CLIA) waivers from the U.S. Food and Drug Administration (FDA). Additionally, the Accula System has received Emergency Use Authorization (EUA) from the FDA for SARS-CoV-2 in vitro diagnostic testing and is now available for use in patient care settings, providing results within 30 minutes, with higher accuracy than other rapid tests on the market. 'Mesa Biotech's innovative platform will enable us to accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care. Since the start of the pandemic, Thermo Fisher has acted quickly to provide support to the scientists and healthcare professionals at the frontlines of combating COVID-19,' said Mark Stevenson, executive vice president and chief operating officer of Thermo Fisher Scientific. 'The addition of Mesa Biotech's easy-to-use, rapid PCR-based test is highly complementary to our existing offering and will further help us meet the continuing demand for COVID-related testing while we work to rapidly scale and develop point-of care tests for other infectious diseases in the future.' Ingo Chakravarty, president and chief executive officer of Mesa Biotech said, 'I am extremely proud of the remarkable accomplishments Mesa Biotech has achieved to date and excited about the prospects of becoming a part of Thermo Fisher. Mesa's innovative rapid PCR platform technology, combining PCR accuracy with mobility and test results in 30 minutes, has already played a meaningful role in the collective efforts combating the pandemic. Thermo Fisher's scale, innovation and global reach will allow us to more significantly amplify the impact our technology will have on human health, during the pandemic, and far beyond.' The transaction is expected to be completed in the first quarter of 2021, subject to customary closing conditions, including regulatory approval. Upon completion, the business will become part of Thermo Fisher's Life Sciences Solutions Segment. About Thermo Fisher Scientific Forward-Looking Statements This communication contains forward-looking statements that involve a number of risks and uncertainties, including statements about the timing of completion of the transaction. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include risks and uncertainties relating to the proposed transaction not being timely completed, if completed at all; regulatory approval required for the transaction not being timely obtained, if obtained at all, or being obtained subject to conditions; and the additional factors set forth in Thermo Fisher's most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, which are on file with the Securities and Exchange Commission and available in the 'Investors' section of its Website under the heading 'SEC Filings.' While Thermo Fisher may elect to update forward-looking statements at some point in the future, Thermo Fisher specifically disclaims any obligation to do so, even if Thermo Fisher's estimates change and, therefore, you should not rely on these forward-looking statements as representing Thermo Fisher's views as of any date subsequent to the date of this communication. Media Contact Information: Investor Contact Information: View original content to download multimedia:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-to-acquire-point-of-care-molecular-diagnostics-provider-mesa-biotech-301210467.html SOURCE Thermo Fisher Scientific |
Company Codes: NYSE:TMO |